CTOs on the Move

Analgesic Solutions

www.analgesicsolutions.com

 
Analgesic Solutions, LLC., founded in 2006, is a privately held consulting company and Clinical Research Organization. We are a hands-on team of experts across a variety of disciplines who consult on and conduct clinical trials aimed at bringing important new pain treatments to market. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the premier choice for providing assistance and training to insure successful pain trials. Clients come to us when looking to develop and commercialize better treatments for pain. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Arturo Morales
Chief Technology Officer Profile

Similar Companies

Graceway Pharmaceuticals

Graceway Pharmaceuticals is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CareMount Medical

We have a number of positions available in our modern medical offices conveniently located at 90 and 110 South Bedford Road in Mount Kisco, as well as openings in our off-site offices in Yorktown, Katonah, Carmel, Fishkill, Poughkeepsie, Somers, Mahopa...

Quartesian

Quartesian delivers quality, expertise, and speed so you can master your data to take control of your clinical trial.

Forma Therapeutics

At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic and metabolic indications.